Cdc7 Antibodies

Santa Cruz Biotechnology delivers a wide array of Cdc7 monoclonal antibodies for research in cell cycle regulation and DNA replication. Cdc7 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Cdc7, a serine/threonine kinase, plays a critical role in the initiation of DNA replication by phosphorylating key substrates involved in the cell cycle. The activity of Cdc7 is essential for the transition from the G1 phase to the S phase, making it a vital component in maintaining genomic stability. Dysregulation of Cdc7 has been implicated in various cancers, highlighting its significance as a potential therapeutic target. Understanding Cdc7's function and regulation is crucial for developing new therapeutic strategies in cancer treatment. Researchers can utilize Cdc7 monoclonal antibodies to explore cellular mechanisms and pathways involved in DNA replication and cell cycle control. The high specificity and reliability of Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of cell cycle regulation and its role in disease development.